Critical Comparison: Clene (NASDAQ:CLNN) versus Aligos Therapeutics (NASDAQ:ALGS)

Clene (NASDAQ:CLNN) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Valuation & Earnings

This table compares Clene and Aligos Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200,000.00	371.66	-$26.17 million	($2.60)	-2.43
Aligos Therapeutics	$2.19 million	18.88	-$24.19 million	($8.59)	-0.78

Aligos Therapeutics has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Clene and Aligos Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1	0	5	0	2.67
Aligos Therapeutics	1	0	3	1	2.80

Clene currently has a consensus target price of $33.00, suggesting a potential upside of 422.98%. Aligos Therapeutics has a consensus target price of $41.50, suggesting a potential upside of 521.26%. Given Aligos Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Clene.

Profitability

This table compares Clene and Aligos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clene	-13,086.50%	N/A	-135.77%
Aligos Therapeutics	-1,106.72%	-28.16%	-20.01%

Insider & Institutional Ownership

23.3% of Clene shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 28.3% of Clene shares are held by insiders. Comparatively, 4.8% of Aligos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Clene has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.62, indicating that its stock price is 162% more volatile than the S&P 500.

Summary

Aligos Therapeutics beats Clene on 10 of the 15 factors compared between the two stocks.

About Clene

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

About Aligos Therapeutics

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.